Binding Sites, Antibody
Fluorescent Antibody Technique
Immunoglobulin Fab Fragments
Antibody-Dependent Cell Cytotoxicity
Molecular Sequence Data
Amino Acid Sequence
Sialic Acid Binding Ig-like Lectin 2
Immunoglobulin Variable Region
Antibodies, Monoclonal, Humanized
Enzyme-Linked Immunosorbent Assay
Tumor Cells, Cultured
Recombinant Fusion Proteins
Immunoglobulin Fc Fragments
Heterocyclic Compounds, 1-Ring
Fluorescent Antibody Technique, Indirect
Xenograft Model Antitumor Assays
Electrophoresis, Polyacrylamide Gel
Immunoglobulin Heavy Chains
Immunoglobulin Light Chains
Antigens, Differentiation, T-Lymphocyte
Antibodies, Monoclonal, Murine-Derived
Dose-Response Relationship, Immunologic
Cell Adhesion Molecules
Complement System Proteins
Sensitivity and Specificity
Complement Fixation Tests
Antigens, Tumor-Associated, Carbohydrate
Hemagglutination Inhibition Tests
Antibodies, Antineutrophil Cytoplasmic
Receptor, Epidermal Growth Factor
Antigens, Differentiation, B-Lymphocyte
Ribosome Inactivating Proteins, Type 1
Killer Cells, Lymphokine-Activated
Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. (1/429)Bispecific monoclonal antibodies (Bi-mAbs) specific for a tumor-associated antigen and the CD3 or CD28 antigen on T lymphocytes represent one of the most successful experimental strategies for the immunotherapy of cancer. We report that the in vivo administration of both alpha-CD3/CD30 and alpha-CD28/CD30 Bi-mAbs results in the specific activation of xenotransplanted, resting human T cells infiltrating the CD30-positive Hodgkin's tumor. Bi-mAb treatment resulted in enhanced expression of cytokines such as interleukin 1beta, interleukin 2, tumor necrosis factor type alpha, and activation markers including Ki-67, CD25, and CD45RO in tumor-infiltrating lymphocytes. This antigen-dependent, local T-cell stimulation led to the activation of the cytolytic machinery in T lymphocytes, determined by the up-regulation of mRNA-encoding perforin and the cytotoxic serine-esterases granzymes A and B. The Bi-mAb-induced generation of CTLs depended on the presence of the CD30 antigen and the combined application of both Bi-mAbs. Our findings suggest that the combined application of T-cell-activating Bi-mAbs is able to achieve a tumor site-specific activation of the T-cell cytolytic machinery in vivo. The fact that these cytotoxic cells do not home in tumor-associated antigen-negative tissue and do not enter circulation might explain our previous observations (C. Renner et al., Blood, 87: 2930-2937, 1996) of a high cure rate in preclinical models even at an advanced stage of disease. (+info)
Dual specificity antibodies using a double-stranded oligonucleotide bridge. (2/429)The covalent conjugation of oligonucleotides to antibody Fab' fragments was optimized by using oligonucleotides modified with a hexaethylene linker arm bearing three amino groups. One oligonucleotide was coupled to antibody of one specificity and a complementary oligonucleotide to antibody of a second specificity. The antibodies were then allowed to hybridize by base pairing of the complementary nucleotide sequences and the generation of bispecific antibody was analyzed on SDS-PAGE and confirmed using BIAcore analysis. The strategy of complementary oligonucleotide-linked bispecific molecules is not limited to antibodies but is applicable to linking any two molecules of different characteristics. (+info)
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules. (3/429)A new, generally applicable procedure is described for the introduction of defined costimulatory molecules into human cancer cells to increase their T-cell stimulatory capacity. The procedure involves infection with Newcastle disease virus to mediate the cell surface binding of costimulatory molecules (e.g., specially designed bispecific antibodies (bsAb)). The modification is independent of tumor cell proliferation and laborious recombinant gene technology and can be applied directly to freshly isolated and gamma-irradiated patient-derived tumor cells as an autologous cancer vaccine. Following the infection of tumor cells with a nonvirulent strain of Newcastle disease virus, the cells are washed and then further modified by coincubation with bsAbs, which attach with one arm to the viral hemagglutinin-neuraminidase (HN) molecule on the infected tumor cells. The second specificity of one bsAb (bs HN x CD28) is directed against CD28 to augment antitumor T-cell responses by selectively channeling positive costimulatory signals via the CD28 pathway. A second bsAb (bs HN x CD3) was produced to deliver T-cell receptor-mediated signals either alone (bsCD3 vaccine) or in combination with anti-CD28 (bsCD3 vaccine plus bsCD28 vaccine). In human T-cell stimulation studies in vitro, the bsCD28 vaccine caused an up-regulation of early (CD69) and late (CD25) T-cell activation markers on CD4 and CD8 T lymphocytes from either normal healthy donors or cancer patients (autologous system) and induced tumor cytostasis in nonmodified bystander tumor cells. In addition, in combination with the bsCD3 vaccine, augmented antitumor cytotoxicity and T-cell proliferative responses were observed. This tumor vaccine modification procedure is highly specific, quick, economic, and has a broad range of clinical applications. (+info)
Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. (4/429)Two bispecific recombinant molecules, an anti-CD3 x anti-carcinoembryogenic antigen (CEA) diabody and a B7 x anti-CEA fusion protein, were tested for their capacity to specifically activate T cells in the presence of CEA-expressing colon carcinoma cells. T-cell activation by the anti-CD3 x anti-CEA diabody required close contact to CEA-positive cells and resulted in diabody-mediated cytotoxicity against the target cells. Additionally, CD28-mediated costimulation in combination with anti-CD3 x anti-CEA diabodies induced activation of autologous T cells in CEA-positive primary colon carcinoma specimens, as determined by flow cytometry. The high specificity of the bispecific diabody approach could be further enhanced by the use of B7 x anti-CEA fusion proteins because the costimulatory CD28-signaling to the T cells strictly depended on the expression of CEA on the target cells. We demonstrate that displaying engagement sites for the T-cell antigens CD3 and CD28 on the surface of colon carcinoma cells is a suitable way to activate and retarget T cells in a highly tumor-specific manner. For clinical purposes, B7 x anti-tumor-associated antigen (TAA) fusion proteins, which are equally effective but more specific compared with anti-CD28 monoclonal anti-bodies, thus may improve the tumor specificity of anti-CD3 x anti-TAA bispecific antibodies. Furthermore, B7-negative tumors can be converted into B7-positive tumors by B7 x anti-TAA fusion proteins without the need for B7 gene transfer to the malignant cells. (+info)
Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. (5/429)The "affinity enhancement system," a two-step targeting technique using bispecific antibody and radiolabeled bivalent hapten, has been reported to be useful for carcinoembryonic antigen-expressing tumors. The purpose of this study was to evaluate the efficacy of this method for targeting human small cell lung cancer using an antineural cell adhesion molecule antibody. METHODS: Antineural cell adhesion molecule/antihistamine bispecific antibody NK1NBL1-679 was prepared by coupling an equimolecular quantity of a Fab' fragment of NK1NBL1 to a Fab fragment of antihistamine 679. Athymic mice inoculated with NCI-H69 small cell lung cancer cells expressing neural cell adhesion molecule were administered bispecific antibody and then 48 h later 125I-labeled bivalent histamine hapten. 125I-labeled intact NK1NBL1 was injected into other groups of mice. Biodistributions were examined as a function of time. RESULTS: In mice of the two-step targeting, tumor uptake was 2.5 +/- 0.2, 3.2 +/- 0.4, 6.4 +/- 2.0, 7.2 +/- 2.7, 6.1 +/- 2.1 and 2.2 +/- 0.4 %ID/g at 5, 30 min, 5, 24, 48 and 96 h, and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 1.4 +/- 1.1, 10.8 +/- 13.2 and 4.6 +/- 4.7, respectively, at 5 h, whereas 125I-labeled NK1NBL1 showed a tumor uptake of 5.7 +/- 0.4 %ID/g and tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios of 0.3 +/- 0.1, 1.1 +/- 0.2 and 0.9 +/- 0.1, respectively, at 5 h. These results were confirmed by autoradiographic studies, which demonstrated clear tumor-to-normal tissue contrast. Dosimetry showed that the affinity enhancement system could enhance the therapeutic potential of the antineural cell adhesion molecule antibody NK1NBL1. CONCLUSION: This two-step targeting method seems promising for the diagnosis and therapy of small cell lung cancer. (+info)
Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. (6/429)We describe the expression of the bispecific antibody biscFv2429 in transgenic suspension culture cells and tobacco plants. biscFv2429 consists of two single-chain antibodies, scFv24 and scFv29, connected by the Trichoderma reesi cellobiohydrolase I linker. biscFv2429 binds two epitopes of tobacco mosaic virus (TMV): the scFv24 domain recognizes neotopes of intact virions, and the scFv29 domain recognizes a cryptotope of the TMV coat protein monomer. biscFv2429 was functionally expressed either in the cytosol (biscFv2429-cyt) or targeted to the apoplast using a murine leader peptide sequence (biscFv2429-apoplast). A third construct contained the C-terminal KDEL sequence for retention in the ER (biscFv2429-KDEL). Levels of cytoplasmic biscFv2429 expression levels were low. The highest levels of antibody expression were for apoplast-targeted biscFv2429-apoplast and ER-retained biscFv2429-KDEL that reached a maximum expression level of 1.65% total soluble protein in transgenic plants. Plant-expressed biscFv2429 retained both epitope specificities, and bispecificity and bivalency were confirmed by ELISA and surface plasmon resonance analysis. This study establishes plant cells as an expression system for bispecific single-chain antibodies for use in medical and biological applications. (+info)
Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. (7/429)Although bispecific IgG molecules have been successfully applied for antibody-mediated immunotherapy of tumours, applicability is hampered by the difficulties associated with their generation. In the present study, we have used a bispecific single-chain diabody (scDb) directed against carcinoembryonic antigen and Escherichia coli beta-galactosidase as a model to generate bispecific IgG-like antibody molecules. We show that the fusion of this single-chain diabody to the Fc (scDb-Fc) or CH3 (scDb-CH3) region of the human immunoglobulin gamma1 chain results in the expression of dimeric fusion proteins exhibiting four functional antigen binding sites with increased functional affinity. This strategy represents a new and convenient way to generate IgG-like multivalent and bispecific molecules that are efficiently secreted from mammalian cells. (+info)
Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. (8/429)Bispecific Abs (bsAb) are promising immunological tools for the elimination of tumor cells in minimal residual disease situations. In principle, they target an Ag on tumor cells and recruit one class of effector cell. Because immune reactions in vivo are more complex and are mediated by different classes of effector cell, we argue that conventional bsAb might not yield optimal immune responses at the tumor site. We therefore constructed a bsAb that combines the two potent effector subclasses mouse IgG2a and rat IgG2b. This bispecific molecule not only recruits T cells via its one binding arm, but simultaneously activates FcgammaR+ accessory cells via its Fc region. We demonstrate here that the activation of both T lymphocytes and accessory cells leads to production of immunomodulating cytokines like IL-1beta, IL-2, IL-6, IL-12, and DC-CK1. Thus this new class of bsAb elicits excellent antitumor activity in vitro even without the addition of exogenous IL-2, and therefore represents a totally self-supporting system. (+info)
There are several subtypes of B-cell leukemia, including:
1. Chronic lymphocytic leukemia (CLL): This is the most common type of B-cell leukemia, and it typically affects older adults. CLL is a slow-growing cancer that can progress over time.
2. Acute lymphoblastic leukemia (ALL): This is a fast-growing and aggressive form of B-cell leukemia that can affect people of all ages. ALL is often treated with chemotherapy and sometimes with bone marrow transplantation.
3. Burkitt lymphoma: This is an aggressive form of B-cell leukemia that typically affects older adults in Africa and Asia. Burkitt lymphoma can be treated with chemotherapy and sometimes with bone marrow transplantation.
4. Hairy cell leukemia: This is a rare type of B-cell leukemia that is characterized by the presence of hair-like projections on the surface of cancer cells. Hairy cell leukemia can be treated with chemotherapy and sometimes with bone marrow transplantation.
The diagnosis of B-cell leukemia is based on a combination of physical examination, medical history, laboratory tests, and biopsies. Treatment options for B-cell leukemia include chemotherapy, bone marrow transplantation, and in some cases, targeted therapy with drugs that specifically target cancer cells. The prognosis for B-cell leukemia varies depending on the subtype of the disease and the patient's overall health.
There are several subtypes of lymphoma, B-cell, including:
1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.
The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.
Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.
Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.
Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.
Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.
Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.
Types of Neoplasms
There are many different types of neoplasms, including:
1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.
Causes and Risk Factors of Neoplasms
The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:
1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.
Signs and Symptoms of Neoplasms
The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:
1. Unusual lumps or swelling
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.
Diagnosis and Treatment of Neoplasms
The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.
The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:
1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.
Prevention of Neoplasms
While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:
1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.
It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.
Bispecific monoclonal antibody
Fragment crystallizable region
Single-chain variable fragment
Patrick A. Baeuerle
James A. Wells
Monoclonal antibody therapy
Chemically linked Fab
Nomenclature of monoclonal antibodies
List of MeSH codes (D12.776)
Rinat Neuroscience Corporation
List of MeSH codes (D12.776.124)
CAR T cell
Cytokine-induced killer cell
Bispecific antibodies for cancer therapy - PubMed
FDA OKs Bispecific Antibody for Rare Lung Cancer Subtype | MedPage Today
A bispecific dsDNAxmonoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus
Targeting Phosphotyrosine in Native Proteins with Conditional, Bispecific Antibody Traps - PubMed
Merus and Selexis Receive Grant for Bispecific Antibody Therapeutics
Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies - Bay City Capital
Nature Medicine Reports Elimination of Large Tumors in Mice by Messenger RNA-Encoded Bispecific Antibodies | DNA RNA and Cells ...
Early Intervention for CRS Is Key for Patients With Multiple Myeloma Receiving Bispecific Antibodies
Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win :: Scrip
Subjects: Antibodies, Bispecific -- adverse effects - Digital Collections - National Library of Medicine Search Results
The eIg technology to generate Ig-like bispecific antibodies. | MAbs;14(1): 2063043, 2022. | MEDLINE
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies | VJHemOnc Podcast |...
Monoclonal Antibody Side Effects | American Cancer Society
Rockland Immunochemicals, Inc. Awarded SBIR Funding for Systemic Pre-targeted Radioimmunothearpy with Bispecific Single Domain...
ProMab Bispecific Antibody Webinar | ProMab
Bispecific Antibodies Pipeline Congress - FLOW CONTRACT SITE
Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus | Technology Transfer
F-star - Peptide Mapping of Bispecific Antibodies - BioPharmaSpec
Antib Ther Volume 6(3); 2023 Jul - PMC
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy<...
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for...
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell...
Clinical | BioWorld
Pharmaceutics | Free Full-Text | Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
The Leukemia & Lymphoma Society Launches First-of-Its-Kind Global Master Clinical Trial for Pediatric Acute Leukemia | Leukemia...
NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer<...
International Hematologic Conference Features UCSF Health Experts | UC San Francisco
WuXi Biologics, ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
- The MajesTEC-1 trial was a pivotal clinical trial that led to the FDA approval for teclistamab-a monoclonal antibody that targets the CD3 receptor on the T-cell and then the BCMA receptor on the myeloma cell. (oncnursingnews.com)
- To make a monoclonal antibody, researchers first have to identify the right antigen to attack. (cancer.org)
- Recombinant humanized IgG1-kappa isotype monoclonal antibody fragment designed for intraocular use. (medscape.com)
- Ublituximab is a CD20-directed monoclonal antibody indicated for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. (medscape.com)
- Merus, which develops bispecific antibody therapeutics to treat cancer patients, and Selexis, which has technologies for biologics drug discovery and Research Cell Bank (RCB) development, received a EUREKA Eurostars grant of €2.1 million (USD 2.33 million) to develop bispecific antibody combination products for the treatment of colorectal cancer, the companies announced on May 20, 2015. (pharmtech.com)
- Utrecht, The Netherlands and Villejuif, France - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced entry into a strategic collaboration to jointly develop bispecific antibodies for therapeutic immuno-oncology applications. (baycitycapital.com)
- November 14th, 2016 - Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $299,625 Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) to develop bispecific single chain recombinant antibodies for pre-targeted cancer diagnostic imaging and treatment. (nsmedicaldevices.com)
- With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged. (pharmtech.com)
- Under the terms of the agreement, Merus and Gustave Roussy will collaborate on the design and conduct of basic, preclinical and translational research studies and early clinical studies leveraging Merus' portfolio of therapeutic human bispecific antibody candidates, including bispecific antibodies in pre-clinical development targeting combinations of immunomodulatory molecules. (baycitycapital.com)
- Our alliance with Merus illustrates our strategic commitment, as one of the leading Comprehensive Cancer Centres in Europe, to actively collaborate with biotech companies developing innovative therapeutic antibodies and biotechnological platforms in the field of precision medicine and immunotherapy," said Professor Alexander Eggermont, General Director of Gustave Roussy. (baycitycapital.com)
- Administering the mRNA encoding the bispecific antibody, thus enabling the patient's body to synthesize the therapeutic protein, may profoundly reduce complexity of drug development. (pipelinereview.com)
- To demonstrate universality of this novel approach, bispecific RiboMABs targeting different tumor antigens were generated, and their therapeutic potency was tested in mice bearing human tumors and repopulated with human immune cells. (pipelinereview.com)
- Bispecific antibodies have emerged as therapeutic molecules with a multitude of modes of action and applications. (bvsalud.org)
- Bispecific antibodies continue to show significant and impressive therapeutic value. (fcslaboratory.com)
- WuXi Biologics ('WuXi Bio') (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47. (biopharmaapac.com)
- 23. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies. (nih.gov)
- About Merus B.V. Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. (baycitycapital.com)
- Antibody therapeutics have great importance for advanced cases of SARS-CoV-2 where a vaccine would not be effective and may be more effective than a vaccine in certain high-risk populations. (nih.gov)
- These recombinant monoclonal antibodies can be used alone, in combination, or with other therapeutics for the treatment of SARS-COV-2. (nih.gov)
- In addition to their potential as therapeutics, these antibodies against SARS-CoV-2 can be used as prophylactics and in assay development. (nih.gov)
- 29. Bispecific antibody based therapeutics: Strengths and challenges. (nih.gov)
- 32. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology]. (nih.gov)
- Recent advances in the generation of bispecific antibodies for tumor immunotherapy. (nih.gov)
- Bispecific antibodies act by connecting human immune cells to tumor cells for highly efficient killing and have demonstrated great promise as immunotherapy agents. (pipelinereview.com)
- Using radiolabeled antibodies, PRIT combines the advantages of radiation's cytotoxic potential with the specificity of tumor-targeting agents. (nsmedicaldevices.com)
- In most cases, tumor-targeting agents are radiolabeled antibodies, which can be used for the diagnosis, detection, and therapy of cancer. (nsmedicaldevices.com)
- Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center. (medicalnewsupdates.com)
- Introduction: Most bispecific antibody (BsAb) therapies focus on stimulating the adaptive immune system, in particular T cells, to promote tumor cell killing. (vumc.nl)
- 21. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. (nih.gov)
- But other monoclonal antibodies act like immunotherapy because they make the immune system respond better to allow the body to find and attack cancer cells more effectively. (cancer.org)
- Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer cells in patients with precursor acute lymphoblastic leukemia and non-Hodgkin's lymphomas. (nature.com)
- 25. Recombinant bispecific antibodies for cellular cancer immunotherapy. (nih.gov)
- 26. Bispecific antibodies for cancer immunotherapy: Current perspectives. (nih.gov)
- 33. Bispecific antibody platforms for cancer immunotherapy. (nih.gov)
- 35. Immunotherapy with bispecific antibodies. (nih.gov)
Proprietary bispecific antibody2
- The company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1. (baycitycapital.com)
- Affimed's AFM13 is a proprietary bispecific antibody designed to bind to CD16a on NK cells and CD30 on lymphoma cells. (medicalnewsupdates.com)
- Recombinant bispecific antibodies for cancer therapy. (nih.gov)
- Scientists at NIAID have developed recombinant monoclonal antibodies that are effective in vitro and in vivo at neutralizing SARS-CoV-2. (nih.gov)
- We describe a modified and improved recombinant envelope domain III-based serologic assay for detecting ZIKV type-specific antibodies in regions with endemic DENV transmission. (cdc.gov)
- Gustave Roussy's outstanding preclinical and clinical oncology teams, coupled with Merus' bispecific antibody pipeline, create a powerful research platform capable of identifying important advancements in the area of immuno-oncology. (baycitycapital.com)
- We are excited to expand our opportunities for collaboration in the development of bispecific antibodies for immuno-oncology," said Professor Jean-Charles Soria, head of the Drug Development Department (DITEP) at Gustave Roussy. (baycitycapital.com)
- F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. (biopharmaspec.com)
- FcγR and FcαRI) to induce antibody-dependent cellular phagocytosis (ADCP) by macrophages or trogoptosis via neutrophils, as well as BsAbs that interfere with checkpoint inhibition, including the SIRPα-CD47 pathway. (vumc.nl)
- In addition, Gustave Roussy will participate in clinical studies of Merus' MCLA-128, a HER2xHER3 bispecific antibody candidate that is designed for the treatment of patients with HER2-expressing solid tumors, and Merus' MCLA-117, a CLEC12AxCD3 bispecific antibody candidate that is designed to recruit and activate T-cells for the treatment of patients with acute myeloid leukemia. (baycitycapital.com)
- Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. (baycitycapital.com)
- Weekly application of any of the bispecific RiboMAB, directed against cancer antigens that are present in many human cancers, resulted in elimination of aggressively growing, large tumors. (pipelinereview.com)
- MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors. (cancer-research-network.com)
- However, the efficiency of mAbs is far from optimal, and antibody engineering is actively used to improve the molecules. (nih.gov)
- The efficacy of the AHP in binding IgG anti-dsDNA antibodies to E was demonstrated in a sensitive and quantitative assay, based on the time resolved fluorescence properties of europium-labeled anti-human IgG mAbs used to probe the E. We also used this assay to screen SLE patient and normal plasmas for levels of anti-dsDNA IgG. (nih.gov)
- These are known as monoclonal antibodies (mAbs or Moabs). (cancer.org)
- Naked mAbs are antibodies that have no drug or radioactive material attached to them. (cancer.org)
- Effects of immuno-related gene polymorphisms on a bispecific antibody targeting colorectal cancer cell. (cdc.gov)
- 2021) Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies. (medicalnewsupdates.com)
- 37. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. (nih.gov)
- Amivantamab is a bispecific antibody that targets EGFR and mesenchymal-epithelial transition factor pathways. (medpagetoday.com)
- In the program, Merus and Selexis will combine their unique and proprietary Oligoclonics and SUREtechnology platforms, respectively, to develop a product combining two, bispecific, full-length immunoglobulin G antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases. (pharmtech.com)
- While the development of bispecific antibodies is an evolving field, many challenges are still awaiting to be solved by experts in the field including target selection, better understanding of their mechanism of action, along with the combination selection of targets. (fcslaboratory.com)
- Furthermore, the specific antibody sequences and targets will inform vaccine development and establishment of long-term immunity. (nih.gov)
- BOSTON Researchers from Memorial Sloan-Kettering Cancer Center presented encouraging, though very early, data on Merus NV's bispecific antibody MCLA-128 for the treatment of patients with NRG-1 gene fusions at the AACR-NCI-EORTC Molecular Targets meeting on Sunday. (bioworld.com)
- Our data show that with low doses of mRNA encoding a bispecific antibody, we get sustained production of RiboMAB comparable to those of naturally produced immunoglobulin proteins and capable of curing advanced cancers in mice," said Prof. Ugur Sahin, founder and CEO of BioNTech, who led the study. (pipelinereview.com)
- Formats included bivalent bispecific IgG -like molecules (eIgs) and Fc-less Fab-eFab fusion proteins , as well as tri- and tetravalent Fab-eIg fusion proteins . (bvsalud.org)
- All proteins , including bispecific antibodies for dual receptor targeting and for retargeting of T cells , efficiently assembled into functional molecules. (bvsalud.org)
- Monoclonal antibodies are man-made proteins that act like human antibodies in the immune system. (cancer.org)
- With our optimized off-the-shelf CHO media and feeds, we will maximize expression of the bispecific antibody combinations generated from Merus' Oligoclonics platform. (pharmtech.com)
- Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia, and Merus expects to initiate clinical trials of this candidate in the first quarter of 2016. (baycitycapital.com)
- Because of their ability to simultaneously bind two different antigens, bispecific antibodies are unique, and their wide potential as targeting reagents has been demonstrated over the years. (nih.gov)
- Our studies indicated that this AHP could bind anti-dsDNA antibodies to E and facilitate clearance of these autoantibodies from the circulation of a monkey without E destruction. (nih.gov)
- Based on whether they are mono-specific or bi-specific and where they bind to the SARS-CoV-2 virus, these antibodies can be subdivided into four groups that target (A) the receptor-binding-domain (RBD) of the SARS-COV-2 spike protein, (B) the N-terminal domain (NTD) of the SARS-COV-2 spike protein, (C) dual locations on the RBD, or (D) both the RBD and NTD. (nih.gov)
- 1 The bispecific antibody was granted accelerated approval for patients with multiple myeloma who have already undergone 4 prior lines of therapy, in October 2022. (oncnursingnews.com)
- Sewnath, CAN , Behrens, LM & van Egmond, M 2022, ' Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer ', Expert Opinion on Biological Therapy , vol. 22, no. 8, pp. 983-995. (vumc.nl)
- This second annual Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific development to improve your candidates' translatability into the clinic. (fcslaboratory.com)
- Identification of vaccine candidates which elicit protective antibodies against SARS-CoV-2 infections. (nih.gov)
- EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (nih.gov)
- Bispecific T-cell engagers (BiTEs) are novel immunotherapeutic molecules that consist of an anti-CD3 single-chain variable fragment (scFv) fused to the scFv targeting antitumor-associated antigen via a flexible linker. (nature.com)
- 39. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions. (nih.gov)
- Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. (baycitycapital.com)
- This is the first preclinical study to demonstrate in vivo application of mRNA-encoded antibodies for successful treatment of cancer. (pipelinereview.com)
- Rockland Immunochemicals, Inc. supports the academic, biopharma, and diagnostic industries with antibodies and antibody based tools used in basic research, assay development, and preclinical studies. (nsmedicaldevices.com)
- Broadly neutralizing antibodies target the coronavirus fusion peptide. (nih.gov)
- Previously we reported the development of an antigen based heteropolymer (AHP), a bispecific complex prepared by using the avidin-biotin system to crosslink dsDNA to a mAb specific for the human erythrocyte (E) complement receptor. (nih.gov)
- An antibody is a protein that sticks to a specific protein called an antigen . (cancer.org)
- Antibodies circulate throughout the body until they find and attach to the antigen. (cancer.org)
- Researchers can design antibodies that specifically target a certain antigen, such as one found on cancer cells. (cancer.org)
- Most serologic assays for flaviviruses measure antibodies binding to viral-envelope glycoprotein (E protein) because this antigen is a major target of human antibodies. (cdc.gov)
- Here, we present a novel approach to solve the light -chain problem for the generation of bispecific Ig-like antibodies using the second constant domain of IgE (EHD2) genetically modified to force heterodimerization. (bvsalud.org)
- Intravenously injecting a few micrograms of mRNA resulted in bispecific RiboMAB production in the liver cells that rapidly secreted into the circulation, reaching peak level within hours and remaining at therapeutically effective plasma concentrations for a week. (pipelinereview.com)
- This Funding Opportunity Announcement (FOA) encourages applications to support the optimization of monoclonal antibodies (mAb) or mAb derivatives that recognize and eliminate cells comprising the HIV reservoir. (nih.gov)
- It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (bvsalud.org)
- 34. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. (nih.gov)
- 27. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture. (nih.gov)
- Rockland received the award because of its strong scientific team and long track record of success in development of antibody reagents for diagnostics and cancer research with the NCI and other major research institutions. (nsmedicaldevices.com)
- Their Modular Antibody Technology™ platform, offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products. (biopharmaspec.com)
- Dr. Chris Chen , CEO of WuXi Biologics, commented, "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody into clinical development through our integrated services and know-how. (biopharmaapac.com)
- At WuXi Biologics, we have demonstrated our extensive capabilities for CMC development, analytical method, and quality control by enabling over 60 bispecific projects. (biopharmaapac.com)
- In lay terms, can you describe the premise of your study that is looking at the development of neutralizing antibodies against SARS-CoV-2? (nih.gov)
- One way the body's immune system attacks foreign substances is by making large numbers of antibodies. (cancer.org)
- 40. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. (nih.gov)
- It has very different advantages that maybe other neutralizing antibodies may not have, and we think we want to contribute to this global research using our unique technologies and expertise. (nih.gov)
- ProMab will be hosting a webinar encompassing our Bispecific Antibody Engineering platform, helping researchers bring personalized medicine closer to reality. (promab.com)
- We previously described a serologic assay using domain III of the ZIKV E protein (EDIII) to detect ZIKV type-specific antibodies among persons in areas with DENV and ZIKV cocirculation ( 19 ). (cdc.gov)
- In Nature Medicine, BioNTech presents the application of this technology for mRNA-based in vivo delivery of T cell engaging bispecific antibodies. (pipelinereview.com)
- NOTE: Some m onoclonal antibodies used to treat cancer are referred to as targeted therapy because they have a specific target on a cancer cell that they aim to find, attach to, and attack. (cancer.org)
- We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-γ, granzyme B, and perforin. (cun.es)
- 22. Bispecific antibodies for immune cell retargeting against cancer. (nih.gov)
- High avidity anti-dsDNA IgG antibodies are believed to play an important role in the pathogenesis of the autoimmune disease systemic lupus erythematosus (SLE) and therefore attempts have been made to reduce the concentration of these antibodies in the bloodstream of SLE patients. (nih.gov)